Press release
Diabetic Neuropathic Pain Pipeline Accelerates With 10+ Novel Therapies in Development, Reports DelveInsight
Diabetic Neuropathic Pain Pipeline
DelveInsight's latest analysis reveals that more than 10 pharmaceutical and biotech companies worldwide are actively advancing over a dozen promising therapeutic candidates for Diabetic Neuropathic Pain. The comprehensive review evaluates ongoing clinical trials, mechanisms of action, routes of administration, and key developmental milestones shaping the future treatment landscape.
Request for sample report - https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from DelveInsight's Diabetic Neuropathic Pain Pipeline Report
• Numerous global players continue to invest in innovative treatment approaches for Diabetic Neuropathic Pain, reflecting steady scientific and clinical advancement.
• Leading Diabetic Neuropathic Pain companies in the development pipeline include Rigshospitalet, CSPC Ouyi Pharmaceutical, Reata, Lexicon Pharmaceuticals, Jemincare, Eli Lilly and Company, GlaxoSmithKline, Apurano Pharmaceuticals, and several others.
• Key investigational therapies currently in various clinical phases include Incobotulinumtoxin-A (100 UNIT Injection), pregabalin sustained-release formulations, RTA 901, LX9211, JMKX000623, LY3556050, GSK3858279, Adezunap (AP707), and more-each anticipated to influence the treatment landscape over the coming years.
Recent Pipeline Developments in Diabetic Neuropathic Pain Pipeline
• March 2025: Lexicon Pharmaceuticals announced positive topline results from the Phase 2b PROGRESS study of LX9211 (pilavapadin), the company's oral AAK1 inhibitor being studied in patients with moderate to severe diabetic peripheral neuropathic pain (DPNP).
• November 2024: Enrollment for Lexicon's Phase IIb PROGRESS trial surpassed expectations, with 494 participants recruited-about 20% above the initial target. Topline data is expected early next year.
• May 2024: Medidata (Dassault Systèmes) partnered with Lexicon Pharmaceuticals to support the advancement of LX9211 trials. LX9211 may become the first new non-opioid neuropathic pain therapy to gain approval in over two decades.
• January 2024: Neuralace Medical received FDA clearance for Axon Therapy (mPNS), marking the first non-invasive magnetic peripheral nerve stimulation device approved for chronic Painful Diabetic Neuropathy (PDN).
Diabetic Neuropathic Pain Overview
Diabetic Neuropathic Pain (DNP) arises from nerve damage caused by persistent hyperglycemia in people with diabetes. It often affects the limbs and causes sensations such as burning, numbness, tingling, or sharp pain. Risk factors include long-standing diabetes, obesity, and poor glycemic control. Treatment strategies typically combine glucose management, pharmacotherapy (including anticonvulsants and antidepressants), and lifestyle modifications.
Download a Free Sample Report: https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Diabetic Neuropathic Pain Pipeline Therapies in Development
Key candidates undergoing clinical evaluation include:
• Incobotulinumtoxin-A 100 UNIT Injection - Rigshospitalet
• Pregabalin SR tablets - CSPC Ouyi Pharmaceutical
• RTA 901 - Reata
• LX9211 - Lexicon Pharmaceuticals
• JMKX000623 - Jemincare
• LY3556050 - Eli Lilly
• GSK3858279 - GlaxoSmithKline
• Adezunap (AP707) - Apurano Pharmaceuticals
Diabetic Neuropathic Pain Drug Classification by Route of Administration (ROA)
Pipeline candidates fall under multiple ROAs, including:
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Diabetic Neuropathic Pain Drug Molecule Types in Development
Therapies are being explored across several molecular categories:
• Small molecules
• Monoclonal antibodies
• Recombinant fusion proteins
• Peptides
• Polymers
• Gene therapies
Comprehensive Diabetic Neuropathic Pain Pipeline Assessment Includes:
• Product type categorization
• Stage-wise progression (Phase I-III, preclinical, discovery)
• ROA-based evaluation
• Molecular classification
• Active vs. discontinued program tracking
DelveInsight's report covers 12+ therapies at various clinical stages, from advanced trials to early discovery.
Download the full pipeline report: https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Leading Companies in the Diabetic Neuropathic Pain Therapeutics Market
Prominent Diabetic Neuropathic Pain Companies include Eli Lilly, Regenacy Pharmaceuticals, Helixmith, Vertex Pharmaceuticals, Eisai, NeuroBo Pharmaceuticals, AstraZeneca, Centrexion Therapeutics, Aptinyx, Pure Green Pharmaceuticals, Dong-A ST, Daiichi Sankyo, NeurogesX, Lexicon Pharmaceuticals, and others.
Diabetic Neuropathic Pain Market Outlook
• Drivers Boosting Market Growth
• Increasing diabetes prevalence
• Rising unmet need for effective pain management
• Ageing population
• Advancements in drug development technologies
• Supportive regulatory incentives
Challenges Hindering Market Expansion
• Complex pathophysiology and variability among patients
• Absence of reliable predictive biomarkers
• Safety concerns in long-term treatments
• Clinical trial design limitations
• Reimbursement and healthcare access barriers
Download Sample PDF Report to know more about Diabetic Neuropathic Pain drugs and therapies
https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Diabetic Neuropathic Pain Clinical Trials Report
• Global: Coverage
• Key Companies: Rigshospitalet, CSPC Ouyi Pharmaceutical, Reata, Lexicon Pharmaceuticals, Jemincare, Eli Lilly, GSK, Apurano Pharmaceuticals, and more
• Key Therapies: Incobotulinumtoxin-A, pregabalin SR tablets, RTA 901, LX9211, JMKX000623, LY3556050, GSK3858279, Adezunap (AP707), etc.
• In-depth analysis of market dynamics, emerging therapies, and development challenges
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Neuropathic Pain Pipeline Accelerates With 10+ Novel Therapies in Development, Reports DelveInsight here
News-ID: 4279002 • Views: …
More Releases from DelveInsight Business Research
Global Acute Myeloid Leukemia Clinical Trial Activity Surges as 110+ Emerging Th …
According to DelveInsight's latest analysis, the global Acute Myeloid Leukemia (AML) pipeline comprises over 100 active companies developing more than 110 therapeutic candidates. The report provides a thorough evaluation of ongoing clinical trials, investigational therapies, mechanisms of action, routes of administration, and recent developmental updates.
The Acute Myeloid Leukemia Pipeline Insight 2025 report offers an extensive commercial and clinical review of AML pipeline products, spanning preclinical stages to marketed therapies. It…
Global Genital Herpes Pipeline Accelerates with 18+ Companies Advancing Novel Tr …
According to DelveInsight's analysis, the global Genital Herpes pipeline features more than 18 key pharmaceutical companies actively developing over 20 therapeutic candidates. The report evaluates ongoing clinical trials, therapy landscapes, mechanisms of action, routes of administration, and key developmental milestones shaping this space.
DelveInsight's "Genital Herpes Pipeline Insight, 2025" report delivers an in-depth review of the current clinical development landscape and future growth outlook of the Genital Herpes market. The study…
Electrosurgical Devices Market Forecasted to Expand at a 6.64% CAGR by 2030, Rep …
The global electrosurgical devices market, valued at USD 8,520.99 million in 2023, is expected to expand at a CAGR of 6.64% between 2024 and 2030, ultimately reaching USD 12,401.80 million. This growth is largely attributed to the rising prevalence of chronic diseases-including cardiovascular, neurological, and gynecological conditions-an increase in surgical procedures, rapid advancements in device technology, and a growing elderly population.
DelveInsight's Electrosurgical Devices Market Insights report offers an in-depth assessment…
Global Nucleic Acid Amplification Testing Market Size to grow at a CAGR of 8.13% …
According to DelveInsight's analysis, The increasing demand for nucleic acid amplification testing (NAAT) is being fueled by several major factors, most notably the growing prevalence of infectious and genetic disorders. This demand is further strengthened by the rising number of cancer cases and the expanding R&D efforts undertaken by key industry participants. Together, these elements are expected to support a strong growth outlook for the NAAT market during the forecast…
More Releases for Diabetic
Exploring The Diabetic Retinopathy Market In A Diabetic-Prevalent World: The Dri …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Diabetic Retinopathy Market Size Growth Forecast: What to Expect by 2025?
The diabetic retinopathy market has experienced robust expansion over the last few years, with projections indicating a rise from $8.61 billion in 2024 next year to $9.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of…
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
